KEYNOTE-012 trial studying HNSCC applied six-gene interferon-γ signature from those eighteen genes, including IDO1, CXCL10, CXCL9, HLA-DRA, STAT1, and IFN-γ (10). This evidence concerns the gene IFNG and head and neck squamous cell carcinoma.